Safety and Efficacy of Firmagon® (Degarelix) for Injection

Ferring Pharmaceuticals368 enrolled

Overview

The purpose of this study is to assess the safety and efficacy of Firmagon® (degarelix) for injection under the conditions of general clinical practice in Korea.

Study Type

OBSERVATIONAL

Enrollment

368

Conditions

Prostate Cancer

Interventions

degarelixDRUG

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who are eligible for the treatment of Firmagon® (degarelix) for injection according to the approved product label, and Firmagon® (degarelix) treatment decided before study enrolment. Moreover, patient should have not previously received Firmagon® (degarelix) for injection before the study commencement date at each site. - Indication: treatment of advanced, hormone-dependent prostate cancer. Exclusion Criteria: * Patients with previous or concurrent known hypersensitivity to any component of the drug.

Locations (1)

Gangnam Severance Hospital (there may be other sites in this country)

Seoul, South Korea

Outcomes

Primary Outcomes

Incidence of adverse events

Time frame: Up to 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.